Sofgen Pharma SAPROCF
13F holders, Q3 2024 (September 30)5holders −2
0new positions
2sold out
$2.21avg. 13F price*
At the end of Q3 2024, 5 institutions reported holding Sofgen Pharma SA (PROCF) in their 13F filings, down 2 from Q2 2024. 0 opened new positions and 2 sold out. The largest holders were Exome Asset Management LLC ($280K), Geode Capital Management, LLC ($64K) and Activest Wealth Management ($22K).
- Company
- Sofgen Pharma SA
- Filed as
- PROCAPS GROUP SA (Q3 2024)
- CUSIP
- L7756P102
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 2 | $32K |
All 13F filers, Q2 2024 → Q3 2024: 12,874 shares sold, net −12,874 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Exome Asset Management LLC | 0.19% | No change | 126,901 | $280K |
| Geode Capital Management, LLC | 0.00% | No change | 28,938 | $64K |
| Activest Wealth Management | 0.01% | No change | 10,000 | $22K |
| Pineridge Advisors LLC | 0.00% | No change | 250 | $550 |
| Morgan Stanley | 0.00% | No change | 100 | $220 |
"% of holder's portfolio" is PROCF's weight in each manager's 13F, not the share of Sofgen Pharma SA the manager owns.